Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.

about

Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.

Item

http://www.wikidata.org/entity/Q40083609

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hepatitis B reactivation chara ...... t after lamivudine withdrawal.

@en

type

Item

label

Hepatitis B reactivation chara ...... t after lamivudine withdrawal.

@en

prefLabel

Hepatitis B reactivation chara ...... t after lamivudine withdrawal.

@en

P1476

Hepatitis B reactivation chara ...... nt after lamivudine withdrawal

@en

P2093

A Battisti

http://www.w3.org/2001/XMLSchema#string

B Mariotti

http://www.w3.org/2001/XMLSchema#string

G Maffongelli

http://www.w3.org/2001/XMLSchema#string

L Colagrossi

http://www.w3.org/2001/XMLSchema#string

L Cudillo

http://www.w3.org/2001/XMLSchema#string

L Sarmati

http://www.w3.org/2001/XMLSchema#string

R Cerretti

http://www.w3.org/2001/XMLSchema#string

V Svicher

http://www.w3.org/2001/XMLSchema#string

P2860

Management of patients with hepatitis B who require immunosuppressive therapy

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem.

Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation

Envelopment of the hepatitis B virus nucleocapsid.

Prophylaxis and treatment of hepatitis B in immunocompromised patients.

Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis.

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification.

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

P2888

s12879-017-2672-6

P304

566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S12879-017-2672-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Romina Salpini

Carlotta Cerva

P577

2017-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091206449

http://www.w3.org/2001/XMLSchema#string

P698

28806922

http://www.w3.org/2001/XMLSchema#string

P932

5557326

http://www.w3.org/2001/XMLSchema#string